These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 16278780

  • 1. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H, Kanatani M, Sugimoto T, Chihara K.
    Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
    [Abstract] [Full Text] [Related]

  • 2. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S, Schwartz Z, Wang L, Lohmann CH, Turner JD, Wieland M, Cochran DL, Boyan BD.
    J Biomed Mater Res A; 2004 Sep 01; 70(3):361-9. PubMed ID: 15293309
    [Abstract] [Full Text] [Related]

  • 3. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K.
    J Cell Physiol; 2004 Oct 01; 201(1):17-25. PubMed ID: 15281085
    [Abstract] [Full Text] [Related]

  • 4. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
    Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF.
    J Bone Miner Res; 2002 Nov 01; 17(11):2068-79. PubMed ID: 12412815
    [Abstract] [Full Text] [Related]

  • 5. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT.
    J Bone Miner Res; 2001 Oct 01; 16(10):1787-94. PubMed ID: 11585342
    [Abstract] [Full Text] [Related]

  • 6. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK.
    Mukohyama H, Ransjö M, Taniguchi H, Ohyama T, Lerner UH.
    Biochem Biophys Res Commun; 2000 Apr 29; 271(1):158-63. PubMed ID: 10777696
    [Abstract] [Full Text] [Related]

  • 7. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 29; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 8. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E.
    Bone; 2005 Jan 29; 36(1):159-72. PubMed ID: 15664014
    [Abstract] [Full Text] [Related]

  • 9. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells.
    Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K.
    Horm Metab Res; 2004 Oct 29; 36(10):674-8. PubMed ID: 15523591
    [Abstract] [Full Text] [Related]

  • 10. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
    Tian QX, Huang GY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug 29; 26(4):418-22. PubMed ID: 15379268
    [Abstract] [Full Text] [Related]

  • 11. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R, Ransjö M, Tatarczuch L, Song SJ, Pagel C, Morrison JR, Pike RN, Mackie EJ.
    J Bone Miner Res; 2004 Mar 29; 19(3):507-16. PubMed ID: 15040840
    [Abstract] [Full Text] [Related]

  • 12. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
    Ishida M, Amano S.
    J Bone Miner Metab; 2004 Mar 29; 22(5):415-29. PubMed ID: 15316862
    [Abstract] [Full Text] [Related]

  • 13. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF, Lie A, Ransjö M.
    J Cell Biochem; 2006 Oct 01; 99(2):528-37. PubMed ID: 16639710
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V, Faust J, Boyle WJ, Dunstan CR, Kelley M, Kaufman S, Scully S, Van G, Lacey DL.
    J Cell Biochem; 1999 Feb 01; 72(2):251-61. PubMed ID: 10022507
    [Abstract] [Full Text] [Related]

  • 16. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H, Nakade O, Takada Y, Kaku T, Lau KH.
    J Bone Miner Res; 2002 Jul 01; 17(7):1219-29. PubMed ID: 12096835
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH, Chang EJ, Kim SJ, Kim HH, Kim HM, Lee SB, Ko JS.
    J Periodontal Res; 2006 Aug 01; 41(4):288-96. PubMed ID: 16827722
    [Abstract] [Full Text] [Related]

  • 19. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S.
    Arthritis Rheum; 2000 Feb 01; 43(2):259-69. PubMed ID: 10693864
    [Abstract] [Full Text] [Related]

  • 20. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
    Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K.
    J Clin Invest; 2006 Feb 01; 116(2):528-35. PubMed ID: 16424941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.